1. Clinical Trials in IBD

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Evolving Treatment Landscape in IBD

4. Conventional Treatments for UC and CD

5. FDA-Approved Biologics for UC and CD

6. UC Treatment Pathway

7. Conventional and Evolving Treatment Strategies for CD

8. Limitations of Current Biologic Treatments for IBD

9. Unmet Therapy Needs in IBD

10. Importance of Randomized, Controlled Trials

11. Challenges in the Current IBD Clinical Trial Environment

12. Evolution of Outcomes Measures in IBD Trials

13. Select Investigational Therapies for UC and CD IL Inhibitors

14. Select Investigational Therapies for UC and CD Other Classes

15. Patient Barriers to Participating in IBD Trials

16. Patient Barriers to Participating in IBD Trials Patient Survey Results

17. Physician Barriers

18. Referring Patients to IBD Trials

19. Participating in an IBD Trial as an Investigator

20. Recruiting and Retaining Patients on Study

21. Novel Trial Designs in IBD

22. Summary and Concluding Remarks

23. Abbreviations